SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.

Autor:	Lu H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Liu C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Velazquez R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Wang H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Dunkl LM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Kazic-Legueux M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Haberkorn A; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Billy E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Manchado E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Moody SE; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Hammerman PS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Mohseni M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Hao HX; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts. huaixiang.hao@novartis.com.
Jazyk:	angličtina
Zdroj:	Molecular cancer therapeutics [Mol Cancer Ther] 2019 Jul; Vol. 18 (7), pp. 1323-1334. Date of Electronic Publication: 2019 May 08.
DOI:	10.1158/1535-7163.MCT-18-0852
Abstrakt:	FGFR1 was recently shown to be activated as part of a compensatory response to prolonged treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic cancer cell lines. We hypothesize that other receptor tyrosine kinases (RTK) are also feedback-activated in this context. Herein, we profile a large panel of KRAS-mutant cancer cell lines for the contribution of RTKs to the feedback activation of phospho-MEK following MEK inhibition, using an SHP2 inhibitor (SHP099) that blocks RAS activation mediated by multiple RTKs. We find that RTK-driven feedback activation widely exists in KRAS-mutant cancer cells, to a less extent in those harboring the G13D variant, and involves several RTKs, including EGFR, FGFR, and MET. We further demonstrate that this pathway feedback activation is mediated through mutant KRAS, at least for the G12C, G12D, and G12V variants, and wild-type KRAS can also contribute significantly to the feedback activation. Finally, SHP099 and MEK inhibitors exhibit combination benefits inhibiting KRAS-mutant cancer cell proliferation in vitro and in vivo These findings provide a rationale for exploration of combining SHP2 and MAPK pathway inhibitors for treating KRAS-mutant cancers in the clinic. (©2019 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu